These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1705999)

  • 1. The threshold of pain and neurotransmitter's change on pain in Parkinson's disease.
    Urakami K; Takahashi K; Matsushima E; Sano K; Nishikawa S; Takao T
    Jpn J Psychiatry Neurol; 1990 Sep; 44(3):589-93. PubMed ID: 1705999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.
    Herbert MK; Kuiperij H; Bloem BR; Verbeek MM
    J Neurol; 2013 Dec; 260(12):3129-33. PubMed ID: 24122060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoamine metabolites and neuropeptides in patients with Parkinson's disease, Huntington's chorea, Shy-Drager syndrome, and torsion dystonia.
    Lindvall B; Olsson JE
    Adv Neurol; 1990; 53():117-22. PubMed ID: 1700581
    [No Abstract]   [Full Text] [Related]  

  • 4. Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
    Nishi K; Kondo T; Narabayashi H; Takubo H; Muramoto S; Araki H
    J Neurol Sci; 1989 Aug; 92(1):65-70. PubMed ID: 2475587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered serotonin metabolism in depressed patients with parkinson's disease.
    Mayeux R; Stern Y; Cote L; Williams JB
    Neurology; 1984 May; 34(5):642-6. PubMed ID: 6200801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system.
    González-Quevedo A; García JC; Fernández R; Fernández Cartaya L
    Bol Estud Med Biol; 1993; 41(1-4):13-9. PubMed ID: 7521168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cerebrospinal fluid study of the pathophysiology of panic disorder associated with alcoholism.
    George DT; Adinoff B; Ravitz B; Nutt DJ; De Jong J; Berrettini W; Mefford IN; Costa E; Linnoila M
    Acta Psychiatr Scand; 1990 Jul; 82(1):1-7. PubMed ID: 1698009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ; Logue M; Growdon JH
    Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotransmitter metabolites in medicated epileptic patients.
    Markianos M; Kalfakis N
    Funct Neurol; 1991; 6(4):367-70. PubMed ID: 1725777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis.
    Lester D
    Pharmacopsychiatry; 1995 Mar; 28(2):45-50. PubMed ID: 7542785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?
    Scheinin M
    Med Biol; 1985; 63(1):1-17. PubMed ID: 2582215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in CSF neurotransmitters in infantile spasms.
    Langlais PJ; Wardlow ML; Yamamoto H
    Pediatr Neurol; 1991; 7(6):440-5. PubMed ID: 1724602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations.
    Losonczy MF; Mohs RC; Davis KL
    Psychiatry Res; 1984 May; 12(1):79-87. PubMed ID: 6205414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms.
    Tong Q; Zhang L; Yuan Y; Jiang S; Zhang R; Xu Q; Ding J; Li D; Zhou X; Zhang K
    Parkinsonism Relat Disord; 2015 Aug; 21(8):882-7. PubMed ID: 26028271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
    Davidson DL; Yates CM; Mawdsley C; Pullar IA; Wilson H
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1136-41. PubMed ID: 591981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [beta-Endorphin and monoamine metabolite concentrations in patients with intractable pain--changes before and after deep brain or spinal dorsal column stimulation].
    Namba S; Fujiwara N; Namba Y; Nishimoto A
    No To Shinkei; 1985 Aug; 37(8):775-83. PubMed ID: 2416330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease.
    Ueda M; Hamamoto M; Nagayama H; Otsubo K; Nito C; Miyazaki T; Terashi A; Katayama Y
    Neurology; 1999 Mar; 52(4):777-81. PubMed ID: 10078727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrections to a 1980 article on CSF monoamine metabolites.
    Faull KF; Berger PA; Kilkowski J; Anderson PJ; Kraemer H; Davis KL; Barchas JD
    Am J Psychiatry; 1989 Jan; 146(1):118. PubMed ID: 2463774
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical and biochemical features of depression in Parkinson's disease.
    Mayeux R; Stern Y; Williams JB; Cote L; Frantz A; Dyrenfurth I
    Am J Psychiatry; 1986 Jun; 143(6):756-9. PubMed ID: 2424323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid neurotransmitter metabolites in neurologically normal infants and children.
    Langlais PJ; Walsh FX; Bird ED; Levy HL
    Pediatrics; 1985 Mar; 75(3):580-6. PubMed ID: 2579365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.